Table 1 Correction between miRNA and related drug resistance in MM patients.
From: Roles of miRNA dysregulation in the pathogenesis of multiple myeloma
miRNA | Drug | Sensitivity | Target | References |
|---|---|---|---|---|
miR-29b | Bortezomib | ↑ | Activating transcription factor Sp1 | [37] |
miR-202 | Bortezomib | ↑ | Inhibiting the activation of JNK/SAPK signaling pathway | [82] |
miR-15a-5p, miR-16-5p, miR-17-5p, and miR-20a-5p | Bortezomib | ↑ | Not mention | [83] |
miR-27a | Bortezomib | ↑ | Inhibiting the expression of oncogene CDK5 | [84] |
miR-137 and miR-197 | Bortezomib | ↑ | Inhibiting MCL-1 expression | [85] |
miR-202 | Bortezomib | ↑ | Inhibiting the activation of JNK/SAPK signaling pathway | [82] |
miR-451 | Bortezomib | ↑ | Inhibiting MDR1 expression | [94] |
miR-202 | Dexamethasone | ↓ | Inhibiting the activation of JNK/SAPK signaling pathway | [82] |
miR-221/222 | Dexamethasone | ↑ | Activating the ATG12/p27-mTOR autophagy-regulatory axis | [86] |
miR-193a | Dexamethasone | ↑ | Inhibiting MCL-1 expression | [87] |
miR-125b | Dexamethasone | ↓ | Inhibiting p53/miR-34a/SIRT1 signaling network | [88] |
miR-137 | Dexamethasone | ↑ | Inhibiting c-MET expression and AKT phosphorylation | [89] |
miR-221/222 | Melphalan | ↑ | Upregulation of the PUMA and modulation of SLC7A5/LAT1 and ABCC1/MRP1 | [90] |
miR-140-5p | Melphalan | ↑ | Inhibiting ATG14 expression | [91] |
miR-451 | Melphalan | ↑ | Inhibiting MDR1 expression | [93] |
miR-152 | Melphalan | ↑ | Inhibiting DKK-1 expression | [94] |
miR-451 | As2O3 | ↑ | Inhibiting MDR1 expression | [93] |
miR-202 | Thalidomide | ↓ | Inhibiting the activation of JNK/SAPK signaling pathway | [82] |
